---
schema_version: "secwatch.filing_event.v1"
accession: "0001376339-26-000074"
form_type: "8-K"
ticker: "MDXG"
cik: "0001376339"
company_name: "MIMEDX GROUP, INC."
filed_at: "2026-07-29T20:08:19+00:00"
generated_at: "2026-07-29T20:09:13.531582+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# MiMedx Q2 net sales $64M (-35% YoY); to acquire Sanara MedTech for ~$350M

## Summary
- Net sales $64M vs $99M YoY; net loss $15M vs net income $10M YoY.
- Surgical product sales +15% YoY; Wound sales -61% YoY due to Medicare changes.
- Acquiring Sanara MedTech (SMTI) for $35/share ($33 cash + 0.4735 MDXG shares); ~$350M enterprise value.
- Consideration represents 46% premium to Sanara's 30-day VWAP; expected close by year-end.
- Financing via cash on hand and $300M term loan from Hayfin; FY2026 net sales guidance reiterated at $260-290M.

## SEC filing metadata
- accession: 0001376339-26-000074
- form_type: 8-K
- ticker: MDXG
- cik: 0001376339
- company_name: MIMEDX GROUP, INC.
- filed_at: 2026-07-29T20:08:19+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1376339/000137633926000074/0001376339-26-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1376339/000137633926000074/mdxg-20260729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001376339-26-000074
- JSON: https://secwatch.observer/filing/0001376339-26-000074.json
- Plain text: https://secwatch.observer/filing/0001376339-26-000074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.